Becton, Dickinson and Company (NYSE:BDX) Stock Position Cut by Public Employees Retirement Association of Colorado

Public Employees Retirement Association of Colorado lessened its stake in Becton, Dickinson and Company (NYSE:BDXGet Rating) by 0.5% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 213,016 shares of the medical instruments supplier’s stock after selling 1,025 shares during the period. Public Employees Retirement Association of Colorado owned 0.07% of Becton, Dickinson and worth $53,569,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Wellington Management Group LLP grew its position in Becton, Dickinson and by 6.1% in the 3rd quarter. Wellington Management Group LLP now owns 14,489,749 shares of the medical instruments supplier’s stock valued at $3,561,871,000 after buying an additional 837,802 shares in the last quarter. Morgan Stanley boosted its position in shares of Becton, Dickinson and by 7.1% during the 3rd quarter. Morgan Stanley now owns 9,827,875 shares of the medical instruments supplier’s stock valued at $2,415,888,000 after purchasing an additional 652,875 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Becton, Dickinson and by 8.3% during the 4th quarter. JPMorgan Chase & Co. now owns 5,048,607 shares of the medical instruments supplier’s stock valued at $1,269,624,000 after purchasing an additional 388,758 shares in the last quarter. Parnassus Investments LLC boosted its position in shares of Becton, Dickinson and by 5.7% during the 3rd quarter. Parnassus Investments LLC now owns 4,706,249 shares of the medical instruments supplier’s stock valued at $1,156,890,000 after purchasing an additional 254,786 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Becton, Dickinson and by 0.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,349,282 shares of the medical instruments supplier’s stock valued at $1,065,733,000 after purchasing an additional 29,522 shares in the last quarter. Hedge funds and other institutional investors own 86.58% of the company’s stock.

BDX has been the subject of several research reports. SVB Leerink raised their price objective on shares of Becton, Dickinson and from $270.00 to $275.00 and gave the company a “market perform” rating in a research report on Friday, February 4th. Wells Fargo & Company upped their price objective on shares of Becton, Dickinson and from $275.00 to $285.00 and gave the company an “equal weight” rating in a research note on Friday, April 1st. StockNews.com raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a research note on Saturday. Morgan Stanley upped their price objective on shares of Becton, Dickinson and from $293.00 to $295.00 and gave the company an “overweight” rating in a research note on Monday, April 11th. Finally, Piper Sandler reduced their price target on shares of Becton, Dickinson and from $265.00 to $255.00 in a research report on Thursday, May 5th. Six equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, Becton, Dickinson and currently has a consensus rating of “Hold” and an average price target of $275.63.

In related news, EVP Betty D. Larson sold 14,374 shares of Becton, Dickinson and stock in a transaction dated Friday, February 25th. The stock was sold at an average price of $271.90, for a total value of $3,908,290.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP David Hickey sold 475 shares of Becton, Dickinson and stock in a transaction dated Friday, May 6th. The stock was sold at an average price of $256.00, for a total value of $121,600.00. Following the completion of the sale, the executive vice president now owns 3,806 shares of the company’s stock, valued at $974,336. The disclosure for this sale can be found here. 0.50% of the stock is owned by company insiders.

NYSE:BDX traded up $3.37 during mid-day trading on Tuesday, reaching $256.26. The stock had a trading volume of 1,000,341 shares, compared to its average volume of 1,333,007. The business’s 50 day moving average is $260.61 and its 200 day moving average is $257.56. Becton, Dickinson and Company has a fifty-two week low of $235.13 and a fifty-two week high of $280.62. The stock has a market cap of $73.05 billion, a P/E ratio of 40.42, a PEG ratio of 4.11 and a beta of 0.64. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.52 and a quick ratio of 1.04.

Becton, Dickinson and (NYSE:BDXGet Rating) last announced its quarterly earnings results on Thursday, May 5th. The medical instruments supplier reported $3.18 EPS for the quarter, beating the consensus estimate of $2.98 by $0.20. The company had revenue of $5.01 billion for the quarter, compared to the consensus estimate of $4.78 billion. Becton, Dickinson and had a return on equity of 14.91% and a net margin of 9.59%. The company’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same quarter last year, the company posted $3.19 earnings per share. Equities analysts expect that Becton, Dickinson and Company will post 11.19 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 30th. Investors of record on Thursday, June 9th will be given a $0.87 dividend. This represents a $3.48 annualized dividend and a yield of 1.36%. Becton, Dickinson and’s dividend payout ratio (DPR) is currently 54.89%.

About Becton, Dickinson and (Get Rating)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

Further Reading

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.